US’ Gilead faces competition from Bangladesh’s Beacon pharmaThe challenger Beacon produces first generic version of Gilead’s newly launched Epclusa — a drug used to treat all types of Hepatitis C DIVYA RAJAGOPAL | ET Bureau | Jul 27, 2016, 08.11 AM IST
MUMBAI: In a classic David Vs Goliath case, the US-based drugmaker Gilead that has made billions of dollars over its blockbuster range of Hepatitis C drugs is facing an unconventional challenger. Beacon Pharma, a little known Bangladeshi drugmaker, has emerged as the David to the Goliath that Gilead is.
Beacon has become the first generic drug company in the world to produce copycat versions of Gilead's newly launched Epclusa (Sofosbuvir + Velpatasvir) — a drug used to treat all types of Hepatitis C infections. One of the revolutionary drugs, Epclusa has a cure rate of 95 per cent, but with a tag of $75,000 it is considered out of reach to even the wealthy.
Beacon, going by its past launches of Hep C drugs, will look at pricing the drug 10x less than that of its originator. "Our brand will be known as SOFOSVEL, this will be the first generic launch of this drug," said Monjul Alam, senior vice-president, Beacon Pharma, to ET over a telephonic chat from Dhaka.
The combination of Sofosbuvir+ Velpatasvir which was approved by the USFDA in June is considered as a path breaking therapy that can be used by even the harshest genotype of patients suffering from the disease. Gilead, which has faced flak for its pricing of other Hep C drugs, has priced this drug lower than its other products. For over 90 low income countries, Gilead has given voluntary licenses to 12 Indian generic makers who are allowed to sell its drugs, in return of a royalty fee. The emergence of companies like Beacon, medical experts say, is also a result of unaffordability of these drugs even in developed nations.
"There is bound to be crossborder movement of any goods that costs $1 in one country and $1,000 in other," said Andrew Hill, Department of Pharmacology and Therapeutics of University of Liverpool.
Beacon is hoping to reach out to patients from 45 countries across the world, including India, through its patient support programme which allows patients to directly purchase the drug through the manufacturer.
There are several Hep C buyers' clubs that have emerged across the world where patients who are unable to afford the costly versions in their home countries, travel to Bangladesh and India to buy the drugs for themselves and fellow patients.
作者: StephenW 时间: 2016-7-29 12:47
美国的吉利德面临来自孟加拉国的灯塔制药竞争
挑战者灯塔产生Gilead公司新近推出的Epclusa的第一个通用版本 - 用于治疗各种肝炎C.DIVYA RAJAGOPAL的药品| ET局| 2016年7月27日，上午08时11 IST